Skip to content
Screener

Exelixis EXEL Payments to Acquire in Process Research and Development

Payments to Acquire in Process Research and Development at other companies

Eli Lilly logo
Eli LillyLLY
$3.28B+2,967%
Immunome logo
ImmunomeIMNM
$9.01M+44.3%
CTO
Citius Oncology, Inc.CTOR
——

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$13.12B+30.3%
Enterprise value$13.01B+29.0%
P/E15.3×-1.5×
P/S5.4×+0.9×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Purchases of marketable securities(342,683)(288,186)
Proceeds from maturities and sales of marketable securities394,393612,021
Purchases of property, equipment and other, net(8,325)(5,790)
Acquired in-process research and development technology(3,025)(20,250)
Net cash provided by investing activities40,360297,795
Cash flows from financing activities:
Payments for repurchases of common stock(753,326)(585,858)
Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan22,91237,710

Item 1. Financial Statements.

FAQ

What is Exelixis's payments to acquire in process research and development?
Exelixis (EXEL) reported payments to acquire in process research and development of $2.5M in Q2 2026.
How has Exelixis's payments to acquire in process research and development changed year-over-year?
Exelixis's payments to acquire in process research and development increased by 233.3% year-over-year, from $750K to $2.5M.
What is the long-term trend for Exelixis's payments to acquire in process research and development?
Over 4 years (2021 to 2025), Exelixis's payments to acquire in process research and development has grown at a 33.2% compound annual growth rate (CAGR), from $10M to $31.5M.
What does payments to acquire in process research and development mean?
Payments to Acquire in Process Research and Development

Ask your AI about Exelixis's payments to acquire in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude